AOD-9604 in Longsha — Fat Loss Peptide Research Guide
AOD-9604 research guide for Longsha. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers trying to source AOD-9604 in Longsha soon discover that local retail options are all but absent from local stores. The core insight for Longsha researchers: sourcing AOD-9604 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. The primary quality indicators for AOD-9604 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. The sections below cover what Longsha researchers need to know about finding, evaluating, and storing AOD-9604 for scientific research use.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Longsha comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
Before assessing any particular supplier, establish a quality benchmark — so you can identify whether a supplier meets the standard. A COA for AOD-9604 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. The combination of peer feedback and direct document verification is the gold standard for AOD-9604 sourcing — community feedback surfaces patterns individual COA review misses, and vice versa. Store lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order AOD-9604 — ships to Longsha
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Temperature excursions — even short periods above −20°C — can partially degrade AOD-9604 without visible changes; always use only material shipped with appropriate cold protection. The main safety concern arising from sourcing in AOD-9604 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Researchers combining AOD-9604 with other compounds should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
